Moderna (MRNA) Tops Q2 EPS by 85c; offers guidance

Moderna (NASDAQ: MRNA) reported Q2 EPS of ($2.13), $0.85 better than the analyst estimate of ($2.98). Revenue for the quarter came in at $142 million versus the consensus estimate of $114.4 million.

GUIDANCE:

Moderna sees FY2025 revenue of $1.5-2.2 billion, versus the consensus of $2.068 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Bimegren Energy (BESS) files $100M mixed shelf
• ShinyHunters hackers say they stole psychiatric and medical records of DBI staff - Reuters